STADA Arzneimittel AG — M&A Activity 2001

Jul 2, 2001

News Details

Ad-hoc | 2 July 2001 08:30

STADA Arzneimittel AG english

Ad hoc announcement processed and transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STADA acquires brand product Plastulen N with DM 5.6 million in annual sales The Bad Vilbel-based pharmaceuticals company STADA is acquiring the brand product Plastulen N from Wyeth on behalf of its German distribution subsidiary NIDDApharm as of 01. July 2001. Plastulen N, which currently generates sales of DM 5.6 million p.a. in the German market, contains the active substances iron and folic acid. It is prescribed by gynaecologists for patients with corresponding deficiencies, in particular during pregnancy. Plastulen N thus effectively complements the existing product portfolio of STADA’s subsidiary NIDDApharm, which already has a gynaecological emphasis with brands such as Magnetrans forte (for high-dose oral magnesium therapy) and Ephelia (hormone plaster for the treatment of postmenopausal complaints). “This product acquisition, which offers a substantial sales volume in a field which lies close to the existing business and which will be easy to integrate into existing business structures, fits well with the planned earnings-oriented expansion of STADA” said Hartmut Retzlaff, Chairman of the Executive Board. The acquisition of the product Plastulen N is part of the strategic expansion of STADA into a broader-based health corporation. In addition to the established focus on generics (largest segment, accounting for 56% of sales in 2000), brands (16% of sales) represent another key core business – insofar as these are available without high-risk and costly research into active substances. Within the framework of this expansion, and following the record year 2000 (which saw sales reach DM 913.7 million), in the first quarter of 2001 STADA again reported double-digit percentage sales growth (+14% YoY) as well as an even stronger rise in EBITDA (+25% YoY). For the year as a whole, the STADA Group is expecting to see sales exceed DM 1 billion for the first time, while EBITDA is set to see substantial double-digit growth. Deutsche Börse AG recently ruled that the STADA ordinary share will rise to the MDAX Index as soon as a place becomes free, by 21 September 2001 at the latest. For further information please contact: STADA Arzneimittel AG / Corporate Communications / D-61118 Bad Vilbel Phone; + 49(0) 6101 603-113 / Fax: + 49(0) 6101 603-506 / E-mail: communication@stada.de Or visit our website at www.stada.de end of ad hoc announcement (c) DGAP 02.07.2001 ——————————————————————————– WKN: 725180; Index: SDax Listed: Amtlicher Handel in Frankfurt (SMAX) und Düsseldorf; Freiverkehr in Berlin, Hamburg, München und Stuttgart 020830 Jul 01